1. Agundez JAG, Garcia-Martin E, Martinez C (2009) Genetically based impairment CYP2C8- and CYP2C-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 5:1–14
2. Ali ZK, Kim RJ, Ysla FM (2009) CYP2C9 polymorphisms: considerations in NSAID therapy. Curr Opin Drug Disc Devel 12:108–114
3. Ashraf E, Ford L, Geetha R, Cooper S (1999) Safety profile of ibuprofen suspension in young children. Inflammopharmacology 7:219–225
4. Ashraf E, Cooper S, Kellstein D, Jayawardena S (2001) Safety profile of non-prescription ibuprofen in the elderly osteoarthritic patient: a meta-analysis. Inflammopharmacology 9:35–41
5. Benjie W, Meiyuan N, Ruichen G (2002) Bioavailability of ibuprofen suspension and tablets in healthy volunteers. Chin J Clin Pharm. doi:
cnkrISSN1007-440602002-01-011